

- Metabolic syndrome, 87, 664
 sleep apnea and, 245
 in women, 709
- Metered-dose inhaler (MDI), 213
- Metformin, for type 2 diabetes, 666, 666t
- Methacholine, in bronchoprovocation testing, 201-202, 202f, 219-220
- Methadone, 1118, 1119t
- Methamphetamine, 1129t-1130t. *see also* Amphetamines.
 chemical structures of, 1134f
- Methanol poisoning, 309
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 916
- Methimazole, 636
- Methotrexate, 587t
 for inflammatory bowel disease, 423
 for rheumatoid arthritis, 774t
 teratogenicity of, 797-798
- α -Methyl dopa, for hypertension, in pregnancy, 177
- Methylenedioxymethamphetamine (MDMA), 1129t-1130t
- Methylenedioxypyrovalerone (MDPV), 1129t-1130t
- Methylone, 1129t-1130t
- Methylphenidate, 1129t-1130t
 for ADHD, 1028
- Methylprednisolone
 for immune thrombocytopenic purpura, 551
 for multiple sclerosis, 1072
 in traumatic spinal cord injury, 1048
- Metoclopramide
 for gastroparesis, 415
 Parkinsonism and, 1018-1019
- Metoprolol succinate, perioperative, with noncardiac surgery, 275
- Metronidazole, for vaginitis, 921
- Metyrapone test, 626t
- Mexiletine, 113, 115t
- Microangiopathic hemolytic anemia (MAHA), 348, 509
- Microangiopathy, thrombocytopenia accompanied by, 570
- Microbiologic flora, normal, 823
- Microcytic anemias, 504-505
- β_2 -Microglobulin
 in end-stage renal disease, 364-365
 in multiple myeloma, 531
- Microscopic polyangiitis (MPA), 233, 320, 793
- Microscopy, urine, for acute kidney injury, 354-355, 355t, 354.e1f
- Microsporidial infection, in HIV-infected patients, 938
- Microtophi, 800
- Microvascular angina, 97-98
- Mid-diastolic murmur, atrial septal defects and, 68
- MIDCAB. *see* Minimally invasive direct coronary artery bypass (MIDCAB).
- Middle cerebral artery (MCA), stroke associated with, 1035, 1038t, 1042
- Middle East respiratory syndrome coronavirus (MERS-CoV), 255, 873
- Middle East respiratory syndrome (MERS), 836-837
- Migraine, 994-997, 1041
 acute attack, 995-996
 auras of, 995, 1058
 with basilar aura, 995
 in children, 995
 classification of, 995t
 complications of, 995
 definition of, 994-995
 familial hemiplegic, 995
 pathophysiology of, 995
 prevention of, 996, 997t
 treatment of, 995, 996f
 in emergency room, 996
 future of, 996-997
- Migraine prophylactic agents, dizziness and, 1012
- Migrainous infarction, 995
- Migraine, 995
- Migrating motor complex (MMC), 404
- Mild cognitive impairment (MCI), 1108
 Alzheimer's disease and, 982
- Miliary tuberculosis, 256
- Milk-alkali syndrome, 743
- Milkman's pseudofractures, 754
- Milrinone, for heart failure, 65
- Mineral acidosis, hyperkalemia and, 305
- Mineral homeostasis, 732-740
 prospectus for future, 740
- Mineralocorticoid activity
 decrease in, 305
 increase in, 303
- Mineralocorticoid deficiency
 in adrenal insufficiency, 643, 645t
 in congenital adrenal hyperplasia, 646
- Mineralocorticoid excess, 647t, 649-650, 650f
- Mineralocorticoid replacement, for adrenal insufficiency, 645
- Mini Mental State Examination (MMSE), 1108
- Minimal change disease, 315-316, 315f
- Minimally invasive cardiac surgery, 148
- Minimally invasive direct coronary artery bypass (MIDCAB), 148
- Minimally invasive therapy, for benign prostatic hyperplasia, 722-723
- Minute ventilation, 192
- Mipomersen, 694
- Mirizzi syndrome, 447-448, 470-472
- Misoprostol, for gastroduodenal ulcer prophylaxis, 409
- Missense mutation, 6
- Mistreatment, in older adults, 1111
- Mitochondrial DNA, disorders associated with, 12
- Mitoxantrone, for multiple sclerosis, 1073
- Mitral regurgitation, 76t, 78t, 82-84, 83f
 in heart failure, 59
 ischemia-induced, 91
 perioperative risk associated with, 278
- Mitral stenosis, 76t, 78t, 80-82, 81f-82f
 noncardiac surgery in patient with, 156
 perioperative risk associated with, 278
 pregnancy in patient with, 156
- Mitral valve, 16
 in auscultation, 30-31
 fibroelastoma of, 145
 opening of, 19f
- Mitral valve prolapse, 82, 83f
- Mixed connective tissue disease (MCTD), 782-783
 systemic sclerosis and, 790
- Mixed etiology dementia, 1108
- Mixed venous PO₂, 199, 199f
- Mixing study, of plasma, 544, 544t, 545f
- Mobitz type I atrioventricular block, 119, 119f
- Mobitz type II atrioventricular block, 119-120, 119f
- Model for End-stage Liver Disease (MELD) score, 468
- Modification of Diet in Renal Disease (MDRD) equation, 292
- MODY. *see* Maturity-onset diabetes of the young (MODY).
- Molecular assays, 831-832, 832f
- Molecular diagnostics, 10-11
- Molecular medicine, 12
- Monoclonal antibodies, as anticancer agents, 588, 590, 590t
- Monoclonal gammopathy, systemic sclerosis and, 790
- Monoclonal gammopathy of uncertain significance (MGUS), 529
- Monocytes, 515f, 517
 blood, 825
 fever and, 835
- Monogenic disorders, 11
 dominant, 11
- Monomorphic ventricular tachycardia (MMVT), 129-130, 130f
- Mononucleosis syndromes, 837
- Monospot test, 843
- Montreal Cognitive Assessment (MoCA), for dementia, 980-981, 981t
- Mood
 changes in perimenopausal transition, 707
 major disorders of, 985-989, 987t
 prospectus for future of, 989
 in older adults, 1108-1109
- Moraxella catarrhalis*, infection with, pneumonia in, 873-874, 874f
- Morphea, 790, 791t
- Morphine, 1118, 1119t, 1129t-1130t
 in acute STEMI, 105
- "Mosaic attenuation" pattern, 215-216
- Motility disorders, esophageal, 399-401
- Motor disorders, esophageal, 400t
- Motor neuron diseases, 1078-1079
 acquired, 1079
 clinical spectrum of, 1079t
 hereditary, 1078.e1t
 prognosis of, 1079
 specific diseases, spinal muscular atrophy, 1079
 symptom management for, 1079t
- Motor system, 1014f
- Motor system disorders, 1013-1023
 central, 1013-1015
 peripheral, 1015
 pyramidal, 1015
 signs and symptoms of, 1013, 1016t
- Motor unit, symptom localization in, 961t
- Motor unit potentials, 1077.e1f
- Movement disorders, 1015-1021
 hyperkinetic, 1017
 hypokinetic, 1017